Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04071756 · ClinicalTrials.gov registry record · Phase 2
Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT04071756 is a Phase 2 study that was terminated before completion, run by Dana-Farber Cancer Institute. The registered enrollment target is 8 participants.
The verdict
NCT04071756, a Phase 2 study, was terminated before completion, sponsored by Dana-Farber Cancer Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
This research is studying the preventative use of topical 0.1% tazarotene gel daily in addition to best practice standards to reduce the development of hand-foot skin reaction (HFSR).
Interventions
- OTHER Placebo
- DRUG Topical Tazarotene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2019-12-30 |
| Est. Completion | 2022-07-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04071756
The ClinicalTrials.gov registry entry for NCT04071756 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04071756 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04071756 about?
NCT04071756 is a clinical study titled "Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions". This research is studying the preventative use of topical 0.1% tazarotene gel daily in addition to best practice standards to reduce the development of hand-foot skin reaction (HFSR).
What is the current status of trial NCT04071756?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2019-12-30. Estimated completion is 2022-07-14.
What interventions are being tested in trial NCT04071756?
The interventions under investigation include: Placebo (OTHER), Topical Tazarotene (DRUG).
Who is sponsoring clinical trial NCT04071756?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.